Printer Friendly

Amarillo Biosciences announces a new clinical trial in patients with bone marrow disorders.

AMARILLO, Texas--(BUSINESS WIRE)--April 24, 1997--Amarillo Biosciences Inc. (NASDAQ:AMAR) announced today that a pilot study has commenced to test low dose oral interferon alpha in 30 patients with rare bone marrow proliferative disorders.

Ten patients each with either agnogenic myeloid metaplasia, polycythemia vera, or primary thrombocytothemia will be given low dose oral interferon alpha daily for 6-12 months as a treatment to relieve the signs and symptoms associated with these disorders.

The study is being conducted at a major Midwestern medical center with a leading medical authority who specializes in the treatment of these myeloproliferative diseases. These rare myeloproliferative diseases are often difficult to treat, generally have a poor prognosis under current treatment regimes, and lead to fatal cancers.

Amarillo Biosciences Inc. is one of the leading companies developing oral interferon alpha as a treatment of a variety of diseases including oral mucositis in cancer patients, hepatitis B, hepatitis C and Sjogren's Syndrome.

CONTACT: Amarillo Biosciences Inc., Amarillo

Charles Hughes, 806/376-1741

e-mail, amacell@arn.net

or

KCSA, New York

Leslie A. Schupak or Joseph A. Mansi, 212/682-6300,

ext. 207/205
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 24, 1997
Words:184
Previous Article:SVI Holdings announces first quarter results.
Next Article:Boole & Babbage MainView Selected to Manage ABN AMRO Bank's Advanced 'Enterprise Server' Operations.
Topics:


Related Articles
Blood cells traced to a common ancestor.
The mandate for investigational cancer therapies.
Bone marrow transplants questioned.
CHINA CERTIFIES PHARMAGENESIS' BONE MARROW STIMULANT PG2.
MGI PHARMA/METHYLGENE BEGIN CLINICAL TRIAL OF MG98.
UMBILICAL-CORD BLOOD CELLS OFFER NEW HOPE.
MARROW TRANSPLANTS SHOWN TO CURE SICKLE CELL DISEASE.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.
CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN EUROPE.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters